5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with Left Ventricular Hypertrophy in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calderone, A; Clement, R; Colombo, F; Gosselin, H; Mercier, I; Pham-Dang, M; Rouleau, JL | 1 |
1 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis.
Topics: Animals; Blood Pressure; Dansyl Compounds; Endomyocardial Fibrosis; Endothelin Receptor Antagonists; Female; Hypertension; Hypertrophy, Left Ventricular; Ovariectomy; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Endothelin | 2002 |